Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (364)	2/8/2006 1:59:29 PM
From: former_pgs	Respond to of 447

My further 2 cents I think deep down, Goddard is rather insecure about his capabilities of developing a novel drug from scratch. All of his acquisitions are attempts to compensate for this weakness, but he doesn't think them through all that well. And, I fear, he's not very good at assessing quality. I'm not entirely sure what made him CEO material to begin with. Tarceva fell in his lap, and every other move he has made has been rather disastrous. I realize he has spent his whole career at OSI and has deep roots in the company, but the board has to seriously look at candidates who can properly steer a company of OSI's stage and capacity.